Biogen is dropping controversial Alzheimer’s drug Aduhelm
Jan 31, 2024
Biogen said it will shift its focus to a newer Alzheimer’s drug, Leqembi, which it markets in a partnership with Japan-based Eisai. Leqembi received FDA approval last year.
Medicare may rethink premium hike for pricey Alzheimer’s drug
Jan 10, 2022
The announcement comes shortly after Aduhelm maker Biogen cut the price of the drug by about half, from $56,000 to $28,000 a year.
Biogen cuts price of controversial Aduhelm in half
Dec 21, 2021
The drug shows promise in clearing the brain plaques believed to play a role in Alzheimer’s disease.
Congressional report slams FDA, drugmaker over approval of Alzheimer’s drug Aduhelm
Dec 29, 2022
The controversy over aducanumab (Aduhelm) stretches back to its June 2021 approval by the US Food and Drug Administration.
Medicare mulls coverage for controversial drug for Alzheimer’s disease
Jul 13, 2021
CMS says a final decision on coverage is not likely until next spring.
Pricey Alzheimer drug drives spike in Medicare B premium: Officials
Nov 15, 2021
New premium will be $170.10 a month, and the $21.60 boost is the biggest increase ever in dollar amount, but not in percentage terms
More news for Wednesday, July 14
By
Alicia Lasek
Jul 14, 2021
Medicare to weigh national coverage for Aduhelm, other Alzheimer’s treatments … Neurologists issue ethical guidance for dementia diagnosis and care … Helping seniors hear better may slow decline...
Medicare will only cover Aduhelm for patients in clinical trials
Apr 08, 2022
The decision is meant to protect patients while gathering more clinical data on whether the medication actually helps slow declines in thinking.
A very troubling $56 billion question
By
John O'Connor
Jul 08, 2021
Considering some of the alternatives, I’m far from convinced that bankrupting Medicare for the sake of Aduhelm would be money well spent.
New Rx instructions tighten use of controversial Alzheimer’s disease drug
Jul 08, 2021
Major changes to prescribing instructions are rare, especially so soon after approval; it change could curb the drug’s use.